Daiichi Sankyo Group is a Winner of the 2016 Global Sustainable Development Award and Accredited as a Global 500 Sustainable Development Agencies of the year 2016 in appreciation of its contribution towards social-economic development of the world and its contribution towards attainment of United Nations Sustainable Development Goals. Recognised for its commitment to attain Sustainable Peace and development through development of treatments for thrombotic disorders. Awarded and Accredited by Public Opinions International (Uganda-East Africa) AND Organisation for International Friends of Africa (OIFA).
Public Opinions International is a Partner and Member of International Organisation for Educational Development (IOED) and International Police Commission which is is duly registered as an international Non-Profit, Non-Secretarial, Peacekeeping and Social Development Paramilitary Organization based in the State of California, United States of America with extension commands in member nations of the U.N.The International Police Commission has also been given the Consultative Status from the UN ECOSOC and it is also a Member of the United Nations Office of the Drugs and Crimes “UNODC.
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a “Hybrid Business Model,” which will respond to market and customer diversity and optimize growth opportunities across the value chain.
Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.
Through the outstanding knowledge and commitment of our 16,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.
Our Mission
To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.
2025 Vision
Global Pharma Innovator with Competitive Advantage in Oncology
- To have Specialty area* business centered on Oncology business as the core business
- To have enriched regional value products** aligned with regional market
- To have innovative products and pipeline changing SOC***
- To realize shareholders’ value through highly efficient management
- *Specialty area: Drugs mainly prescribed at Hospital and/or by Specialty practitioners
- **regional value products: Products aligned with regional market
- ***SOC: Standard of Care
Core Values and Commitments
In alignment with our mission, we have identified “Core Values and Commitments” as the basis for an attitude of cooperation and proper value judgments and as the criteria for our business activities and decision making. In addition, we have established the DAIICHI SANKYO Group Corporate Conduct Charter* to act with the highest ethical standards and a good social conscience appropriate for a company engaged in a business that affects human lives.
Core Values comprise the following: Innovation, Integrity, and Accountability.
Based on our “Core Values”, we have formulated our “Commitments”. Each member of DAIICHI SANKYO should look back to the Core Values and Commitments before embarking on a course of action.
Core Values
- Innovation
- Integrity
- Accountability
Notes
Innovation ──── | the introduction of new ideas, methods, or invention |
---|---|
Integrity ────── | the quality of being honest and of always having high moral principles |
Accountability ──── | being responsible for the effects of your actions, and being willing to explain or be criticized for them |
Commitments
- 1. To create innovative medicines changing SOC*1
- *1 SOC (Standard of Care) : Universally applied best treatment practice in today’s medical science
- 2. To take a global perspective, and respect regional values
- 3. To foster intellectual curiosity and strategic insight
- 4. To provide the highest quality medical information
- 5. To provide a stable supply of top-quality pharmaceutical products
- 6. To be an ethical, trusted, and respectful partner
- 7. To be accountable for achieving our goals
- 8. To demonstrate professionalism, respect for others and teamwork
Corporate Conduct Charter
The Daiichi Sankyo Group Corporate Conduct Charter lays out the ten articles representing the most important principles of action related to corporate quality. All Group companies both in and outside Japan must observe these principles, which form the basis for the Group’s CSR.
DAIICHI SANKYO Group Corporate Conduct Charter
The DAIICHI SANKYO Group fulfills its mission to “To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, and through the provision of pharmaceuticals addressing diverse medical needs.” We comply with laws, regulations and rules regarding global corporate activities, and act with the highest ethical standards and a good social conscience appropriate for a company engaged in a business that affects human lives based on the following principles. We fulfill our corporate social responsibility (CSR) by actively responding to an ever-changing society and enacting improvements for corporate value.
Article 1
We diligently address medical needs by providing beneficial, safe, and reliable pharmaceuticals and services.
Article 2
We conduct business in an ethical, fair and competitive manner, and maintain a healthy and professional relationship with our stakeholders, which include medical professionals and governments.
Article 3
We actively communicate with our stakeholders by disclosing corporate information in a timely and appropriate manner in accordance with the principles of corporate accountability. We take appropriate measures to manage and protect personal and customer information and the confidential information of our and other companies.
Article 4
The globalization of business activities requires that we operate by being compliant with the laws of each country and region, and by being respectful to all international norms including human rights, various cultures and customs. As a result, we contribute to the development of the local economy and society.
Article 5
We respect diversity in the personal values, qualities and individuality of our employees, and ensure a safe and working environment that does not tolerate inappropriate treatment such as discrimination or harassment. We provide employees the opportunity to develop their skills and abilities for the mutual development of the employee and the corporation.
Article 6
We responsibly manage the environmental impact of our operations as environmental issues are common challenges for mankind and such concerns are integral to our corporate activities and our very survival.
Article 7
We actively engage in community activities and philanthropic programs focused on social causes.
Article 8
We do not support or conduct our business with antisocial forces, prohibited entities or groups that may threaten the order or safety of civil society.
Article 9
Executives of the DAIICHI SANKYO Group actively build and maintain effective systems to implement this Charter, ensure it is understood by all Group companies and make this Charter known to our business partners.
Article 10
If the Charter is violated, executives of DAIICHI SANKYO Group Companies ensure that there is a commitment to determine the cause of infringement, take corrective action as necessary and make efforts to prevent similar violations in the future. Executives are accountable for promptly making required disclosures and upon discerning responsibility regarding the infringement, impose appropriate disciplinary action, including upon Executives themselves.
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and Sankyo, Daiichi Sankyo delivers innovative products that enhance the lives of millions of people around the world. Our recent successes include the antihypertensive agent olmesartan (Olmetec®), launched in 2002 by Sankyo and now available in more than 20 countries around the world; the antiplatelet agent prasugrel (Efient®), launched in 2009 for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI); and edoxaban (Lixiana®), the first available factor Xa inhibitor in Japan, which launched in 2011 to help prevent venous thromboembolism (VTE).
R&D Strategy and Organization
Through the inquisitive spirit of our researchers, alongside our desire to contribute to the betterment of humanity, we’re working to create a competitive pipeline and quickly and consistently deliver innovative products. This supports our vision of becoming a Global Pharma Innovator with Competitive Advantage in Oncology.
Research and development stage priority areas
By implementing research and development initiatives that precisely address unmet medical needs our Group is contributing to improve the rate of satisfaction towards medical care in future. Defining oncology as a primary focus area, we also aim to create advanced new drugs that revolutionize the SOC by advancing research and development targeting pain management, central nervous system disease, heart and kidney disease, and rare diseases as new horizon areas.
At the late-stage of development, in addition to oncology and cardiovascular-metabolics we are developing approaches to provide new treatment options for pain management.
Finally, in the life cycle management phase, we aim to provide continued medical benefits focused on our areas of strength, such as pain management, hypertension and thrombotic disorders.
Global decision-making and effective resource investment
The Daiichi Sankyo Group actively conducts discussions with scientific and business viewpoints in mind from the research stage, and endeavors to achieve more effective investment of manpower and material resources from a global perspective. Furthermore, we are constantly improving the meeting process and achieving swift decision-making while actively delegating authority. In particular, the Global Executive Meeting of Research And Development (GEMRAD), which makes “go/no-go” decisions on late-stage development projects, and Translational Research-GEMRAD (TR-GEMRAD), which handles early-stage development projects, have been established. As top decision-making bodies, they manage global R&D activities across functions and regions. Their members represent various divisions, including those responsible for R&D, pharmaceutical technology, product portfolios, licensing, pharmacovigilance, and finance, enabling both bodies to make appropriate decisions based on comprehensive assessments covering everything from research to marketing.
Moreover, global Integrated Project Teams (IPTs) and Translational Research Project Teams (TR-PTs) work under GEMRAD and TR-GEMRAD in a simple structure to propose project strategies and implement project plans, enabling fast and high quality project activities.
Regular priority evaluation is also conducted for early-stage development projects in progress, enabling effective resource investment based on portfolio strategy.
As of July 2016
Innovation born from diversity
Daiichi Sankyo Group research is carried out globally via a closely integrated network incorporating Japan, the United States, Germany and India. In Japan, alongside the nucleus of Daiichi Sankyo, there is Daiichi Sankyo RD Novare, which is responsible for technology platforms for drug development, and Asubio Pharma, which specializes in drug development research. Overseas, there is Plexxikon, which utilizes small molecule scaffold-based drug discovery, Daiichi Sankyo Life Science Research Centre in India (RCI), which focuses on creating drugs for inflammatory and infectious diseases, and the Tissue and Cell Research Center Munich (TCRM), which utilizes tissue research technology. Each advances new drug research by utilizing their respective strengths. Also, the Venture Science Research Laboratories based in Shinagawa, Tokyo, carries out innovative drug development research to find treatment for diseases with high unmet medical needs.
Our Group is unified across borders from Japan, the United States, and Europe, as well as bases across Asia, including India, South Korea and China, to advance global development by delivering drugs to more people around the world.
* An unincorporated division of Daiichi Sankyo, Inc.
Acceleration of Oncology R&D
While the medical needs of cancer are far from being fully addressed and new cancer cases are expected to rise from 14 million to 22 million over the next two decades. Moreover, as cancer rates increase with age, the ongoing aging of our society demands the rapid and timely delivery of innovative new cancer treatments to patients.
Defining oncology as a primary focus area in research and development, the Daiichi Sankyo Group has established a new global oncology research and development subunit unifying our research functions, including low-molecular-weight drugs and cancer biology and immunology, from research to development. Working together as a single expert team with high quality science and unified strategies, we continue to accelerate oncology R&D by rapid decision making. We make our best efforts to execute the delivery of new cancer treatments to patients as quickly as possible.
Open Innovation
In order to quickly and consistently create competitive pipelines and innovative drugs, it is necessary to gather knowledge from both within and outside the company. The Daiichi Sankyo Group is actively advancing open innovation, and the TaNeDS Europe Programme, established in 2011, is one part of this. The program is continuing to achieve research results through collaboration, and the TaNeDS Global Program, which includes all EU member countries plus Norway and Switzerland, is having similar success.
In November 2013, a three-way research partnership was formed with two US companies Virtici and Celdara Medical, utilizing their academic connections to advance new drug discovery initiatives.
Even more recently, in April 2014, an agreement was signed with Astellas Pharma to enable the mutual exchange and use of each other’s chemical compound libraries, totaling around 400,000 compounds, for three years.
Through such initiatives maximizing efficient use of resources and knowledge, we hope to continue to achieve innovative drug creation.
Daiichi Sankyo is based in Tokyo and today has 50 billion yen in capital.
Daiichi Sankyo Co., Ltd. Head Office
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo
103-8426, Japan
Phone: +81-3-6225-1111
For more information, please visit: daiichisankyo.com.
Public Opinions International
Organisation for International Friends of Africa (OIFA)
Plot 30 Suite 5, Level 4 Green Land Tower
Opposite Bank of Uganda Kampala Road
P.o Box 35297 Kampala-Uganda
Tel: 256 701 992 426
Email:[email protected]
Web: www.pubopinions.org